Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I dose-escalation sequential-cohort of the safety tolerability and pharmacokinetics of intravenous AVE005 [aflibercept] (VEGF Trap) administered every 2 weeks in combination with weekly intravenous gemcitabine then with biweekly intravenous gemcitabine plus oxaliplatin in subjects with advanced solid malignancies

Trial Profile

A phase I dose-escalation sequential-cohort of the safety tolerability and pharmacokinetics of intravenous AVE005 [aflibercept] (VEGF Trap) administered every 2 weeks in combination with weekly intravenous gemcitabine then with biweekly intravenous gemcitabine plus oxaliplatin in subjects with advanced solid malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jun 2008 Interim results were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.
    • 07 Aug 2006 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top